In the NEJ026 study, the PFS was longer in patients receiving erlotinib plus bevacizumab than in patients receiving erlotinib plus placebo as a first-line therapy for EGFR-mutant NSCLC (16.9 vs. 13.3 months, p = 0.016) [16]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.